CMS will publish the first 10 Medicare drugs selected under the Medicare Drug Price Negotiation Program established in the Inflation Reduction Act, this year. This workshop will provide an in-depth overview of what’s included in the IRA and how it will impact Part D plans moving forward. Delve into the regulations, mechanics and implementation challenges associated with:

• Key provisions in the Inflation Reduction Act including Medicare drug price negotiation program Part D Redesign: Medicare Part D brand name drug costs and spending caps
• Premium benchmark stabilization vs. actual Part D plan premiums
• Projecting the impact on overall plan costs Examining opportunities to mitigate the impact through formulary design and utilization management
• Part D “smoothing” of cost sharing and operational challenges